News · Clinical trials

STEP UP: Semaglutide 7.2 mg Reports 20.7% Weight Loss, Narrowing the Gap With Tirzepatide

A threefold increase on the approved dose brings semaglutide close to tirzepatide's SURMOUNT-1 figure — if tolerability holds.

Event date 2026-06-13 · Published 2026-07-24 · EV-0812

What was reported

The STEP UP trial evaluated semaglutide at 7.2 mg — roughly three times the 2.4 mg approved for weight management — and reported 20.7% mean weight loss.

That figure sits close to the approximately 20.9% reported for tirzepatide 15 mg in SURMOUNT-1, and materially above the 13.7% semaglutide recorded against tirzepatide in the SURMOUNT-5 head-to-head, where semaglutide was dosed at its approved maximum of 2.4 mg.

Why this matters for the head-to-head narrative

SURMOUNT-5 is frequently summarised as demonstrating that tirzepatide's dual GIP/GLP-1 mechanism is superior to GLP-1 alone. That reading has always had a caveat: the trial compared each drug at its approved maximum, and those maxima were set by separate development programmes rather than by any principle of equivalence.

If semaglutide at 7.2 mg approaches tirzepatide's result, the mechanism argument weakens and a dose argument strengthens. The observed difference may reflect how much drug each product delivers at its approved ceiling rather than something intrinsic about acting on two receptors instead of one.

That is a meaningful reframing, and it is not settled by a single trial readout.

The question the trial exists to answer

Tolerability. Gastrointestinal adverse effects in this class are dose-related, and they are the primary driver of discontinuation. In SURMOUNT-1, 4.3% to 7.1% of participants discontinued for adverse events depending on dose.

A dose that produces more weight loss and more discontinuation may deliver less benefit in practice than a lower dose people stay on. That is why the treatment-policy estimand — which includes everyone regardless of adherence — matters more at higher doses than at lower ones.

We have not seen the tolerability and discontinuation data for 7.2 mg, and we are not charting the efficacy figure alongside approved-dose results until we have. A weight-loss number without its discontinuation rate is half a result.

What it would change if approved

For patients, a higher-dose option within a familiar molecule and a known safety profile — potentially useful for people who tolerate semaglutide well but plateau below their target.

For the market, it would compress the efficacy spread between the two dominant molecules, which currently underpins tirzepatide's price premium. Tirzepatide is priced above semaglutide almost universally: $186 against $145 at one provider in our dataset, $199 against $133 at another, $278 against $178 at a third.

If the efficacy gap narrows, that premium becomes harder to justify.

Status

Semaglutide 7.2 mg is not approved. It is not available from any provider, and it cannot lawfully be compounded — compounding a copy of an available approved product is generally not permitted, and this is not an approved product at all.

Anything sold today as high-dose semaglutide is either an approved product being used off-label at a prescriber's direction, or something outside the regulated supply chain. Those are very different situations and the difference is worth establishing.

Questions readers actually ask

Capture standing: 35 of 86 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.